Objective: This study investigates the clinical efficacy and toxicity of centrally located early lung cancer treated by stereotactic radiotherapy. Methods: We retrospectively reviewed 17 patients with centrally located non-small cell lung cancer staged T1/T2N0M0 from November 2006 to December 2010. The differences in the position and stage of tumors were considered. Different segmentations were performed in the lesions. The median prescription dose was 56 Gy (range: 48 Gy to 60 Gy), which was delivered into five fractions (range: 3 fractions to 10 fractions). The median planning target volume was 46.2 mL (range: 13.8 mL to 92.2 mL). Results: Nine patients achieved complete response, seven patients achieved partial response, and one patient achieved stable disease three months after treatment. The treatment response rate was 94.1% with a median follow-up of 19.5 months (range: 4 months to 64 months) and median survival time of 43 months. The local control, progress free survival and overall survival rates of patients at one and two years were 100% and 87.5%, 80.8%and 67.3%, and 77.3% and 53.3%, respectively. In the follow-up period, toxicities related to treatment, such as dyspnea, fatigue, and at-electasis, were observed. One patient developed Grade 3 toxicity, whereas no patient developed Grades 4 to 5 toxicities. Conclusion: On the basis of the position and stage of tumors, centrally located lung cancer can be safely and effectively treated by stereotactic radiotherapy with different segmentations.% 目的：探讨立体定向放射治疗早期中央型肺癌的临床疗效及不良反应.方法：回顾性分析2006年11月至2010年12月立体定向放射治疗的17例分期为T1/T2N0M0的中央型非小细胞肺癌患者,根据肿瘤位置及分期,给予不同的分割剂量,中位处方剂量56(48~60)Gy,中位分割次数5(3~10)次,中位治疗体积46.2(13.8~92.2)mL.结果：治疗后3个月疗效评价：9例病变完全缓解,7例部分缓解,1例稳定,治疗反应率94.1%；中位随访期19.5(4~64)个月,中位生存时间43个月,1、2年局控率、无进展生存、总生存分别为100%、87.5%,80.8%、67.3%和82.4%、68.4%.随访期内见呼吸困难、疲劳、肺不张等不良反应,其中3级不良反应1例,未见4~5级不良反应.结论：根据肿瘤位置及分期不同,给予不同的剂量分割模式,立体定向放疗可以较好的应用于早期中央型肺癌的治疗.
展开▼
